<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20080921001264N13</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-31</date_registration>
      <primary_sponsor>Gorgan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of bolus injection of phenylephrine and norepinephrine in preventing hypotension after spinal anesthesia in patients undergoing elective cesarean elective.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of bolus norepinephrine and phenylephrine for prophylaxis against  post spinal anesthesia hypotension during elective caesarean delivery: A randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67610</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Health service research, Other design features: The study is designed in a random manner and after approval by the ethics committee of the university and registration in the clinical studies system of Iran, the consent form is fully explained to all pregnant women who are part of the study criteria. By meeting the existing conditions and understanding the informed consent, consent to conduct the study is obtained from them.</study_design>
      <phase>2</phase>
      <hc_freetext>Complications of anesthesia during the puerperium.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: NE norepinephrine group: 45 people: these people receive NE with a dose of 5 micrograms. Intervention 2: Control group: Phenylephrine PE group: 45 people: these people receive PE at a dose of 50 micrograms.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after de-identifying individuals

When:
The access period starts 6 months after the results are published

To whom:
Our data will be available only to researchers working in academic and scientific institutions, and also people who work in industry can apply to receive them.

Conditions:
To promote science

Where to obtain:
Dr. Saideh Yazdanpanah      sepideh.yp.md@gmail.com
Dr. Sima Basharat                 sbesharatgp@gmail.com
Dr. Erazberdi Ghourchaei      arazberdi@gmail.com

How to obtain:
After sending an e-mail and a comprehensive explanation about the reason for using the data files, and after consulting with the rest of the project members, the data will be provided within 15 days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Erazbardi Ghorchaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>3rd floor- Martyr Khemet Dr. Abdullah Abbasi Heart Superspeciality Center-Martyr Sayad Shirazi Hospital-Gorgan</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4917867439</zip>
        <telephone>+98 17 3245 1660</telephone>
        <email>ghourchaeiarazberdi@gmail.com</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Sima Basharat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>3rd floor- Shahid Dr. Abdullah Abbasi Heart Superspeciality Center- Shahid Sayad Shirazi Hospital- Gorgan</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4917867439</zip>
        <telephone>+98 17 3225 1910</telephone>
        <email>sbesharatgp@gmail.com</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The participants in this study include pregnant women, 36 to 41 weeks, between 18 and 45 years old, who referred to Sayad Shirazi Hospital in Gorgan. 
These patients are candidates for elective Cesarean elective
Do not have any restrictions for spinal anesthesia such as patient's lack of consent, sensitivity to anesthesia, injection site infection, and high intracerebral pressure.
Patients who enter the study in case of failure of spinal anesthesia, unpredictable complications during surgery, such as bleeding during surgery more than normal for a cesarean section without problems (more than 1500 ml) and the sensory level of T4 is higher than are excluded from the study.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>At the beginning of the study, patients with uncontrolled heart complications, high blood pressure disorders in pregnancy, diabetes, psychiatric and renal problems, systolic blood pressure less than 90 mm Hg, peripheral bleeding, coagulation disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O89</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Complications of anesthesia during the puerperium</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: NE norepinephrine group: 45 people: these people receive NE with a dose of 5 micrograms.</i_keyword>
      <i_keyword>Control group: Phenylephrine PE group: 45 people: these people receive PE at a dose of 50 micrograms.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>In the first few minutes after the injection of both drugs, we expect an increase in blood pressure, and we also expect to maintain the heart rate after the use of norepinephrine. Timepoint: It was monitored every 2 minutes to 6 minutes, every 3 minutes to 15 minutes and every 5 minutes until the end of the surgery. Method of measurement: An increase in blood pressure was calculated as an increase in systolic pressure greater than 120% of baseline and a drop in blood pressure was calculated based on a decrease in systolic blood pressure below 80% of baseline.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Due to the short half-life of the drug, which is up to 3 minutes, and its metabolite is also inactive, we do not expect secondary effects. Timepoint: 5 minutes later. Method of measurement: In this study, an increase in blood pressure is calculated as an increase in systolic pressure more than 120% of the baseline, and a drop in blood pressure is calculated based on a decrease in systolic blood pressure below 80% of the baseline.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gorgan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-11-14</approval_date>
        <contact_name>Ethics committee in biomedical research of the Gorgan University  of Medical Sciences</contact_name>
        <contact_address>3rd floor- Shahid Dr. Abdullah Abbasi Heart Superspeciality Center- Shahid Sayad Shirazi Hospital- Gorgan Gorgan Golestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
